- Home
- NRXS vs LONA Comparison
NRXS vs LONA Comparison
Compare NRXS & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | LONA |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 53.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXS | LONA |
|---|---|---|
| Price | $6.26 | $6.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 113.9K | 52.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,685,925.00 | N/A |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $146.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.18 | N/A |
| 52 Week Low | $1.33 | $4.21 |
| 52 Week High | $6.35 | $6.61 |
Technical Indicators
Market Signals| Indicator | NRXS | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 64.37 | 61.24 |
| Support Level | $2.32 | $4.34 |
| Resistance Level | $6.20 | N/A |
| Average True Range (ATR) | 0.46 | 0.51 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 76.00 | 84.70 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).